Tweet
When Pomalidomide is used with bortezomib and dexamethasone in patients who have previously received at least one other type of drug therapy, it can stop the worsening of multiple myeloma: on average, when using Pomalidomide with bortezomib and dexamethasone, the disease did not return for up to 11 months - compared with patients receiving only bortezomib and dexamethasone, for whom this period was 7 months. Pomalyst (Pomalidomide) cost is not affordable for all MM patients. When Pomalidomide is used with dexamethasone in patients who have received at least two other types of drug therapy, it can stop the worsening of multiple myeloma: on average, when using Pomalidomide with dexamethasone, the disease did not return for up to 4 months - compared with patients who received only dexamethasone, for whom this period was 2 months.